TLR3 and neoplasm: Nevertheless, the combination of the anti-PD-L1 antibody with TLR3 specific adjuvant (ARNAX + tumor Antigen) induced a more effective tumor regression response in a mouse model.90 And the evaluated proliferation of antigen-specific CTLs of human peripheral blood mononuclear cells (PBMCs) was observed induced via ARNAX treatment combined with TAA.